STOCK TITAN

Arcus Biosciences Announces New Employment Inducement Grants

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity awards to four new employees. The grants include options to purchase 14,100 shares of common stock at an exercise price of $17.85 per share, which was the closing price on November 8, 2024. Additionally, the employees received restricted stock units to acquire 7,050 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.

Arcus Biosciences (NYSE:RCUS) ha annunciato che il suo Comitato per la Retribuzione ha concesso premi azionari a quattro nuovi dipendenti. I premi includono opzioni per acquistare 14.100 azioni ordinarie a un prezzo di esercizio di 17,85 dollari per azione, che corrisponde al prezzo di chiusura dell'8 novembre 2024. Inoltre, i dipendenti hanno ricevuto unità di azioni ristrette per acquisire 7.050 azioni. Questi premi azionari sono stati concessi nell'ambito del Piano di Induzione 2020 della Società, approvato dal Consiglio di Amministrazione nel gennaio 2020 ai sensi della 'eccezione di induzione' della Regola 303A.08 del Manuale delle Aziende quotate NYSE.

Arcus Biosciences (NYSE:RCUS) anunció que su Comité de Compensación otorgó premios en acciones a cuatro nuevos empleados. Las concesiones incluyen opciones para comprar 14,100 acciones ordinarias a un precio de ejercicio de $17.85 por acción, que fue el precio de cierre del 8 de noviembre de 2024. Además, los empleados recibieron unidades de acciones restringidas para adquirir 7,050 acciones. Estos premios en acciones fueron otorgados bajo el Plan de Inducción 2020 de la Compañía, aprobado por la Junta Directiva en enero de 2020 bajo la 'excepción de inducción' de la Regla 303A.08 del Manual de Empresas Listadas de NYSE.

Arcus Biosciences (NYSE:RCUS)는 보상 위원회가 네 명의 신입 직원에게 주식 관련 보상을 부여했다고 발표했습니다. 보상에는 14,100주를 $17.85의 행사가로 구매할 수 있는 옵션이 포함되어 있으며, 이는 2024년 11월 8일의 종가입니다. 또한 직원들은 7,050주를 취득하기 위한 제한 주식 단위를 받았습니다. 이러한 주식 보상은 2020년 1월 이사회에 의해 승인된 회사의 2020 유도 계획에 따라 부여되었습니다. 이는 NYSE 상장 회사 매뉴얼 규칙 303A.08의 '유도 예외'에 해당합니다.

Arcus Biosciences (NYSE:RCUS) a annoncé que son Comité de Rémunération a accordé des attributions d'actions à quatre nouveaux employés. Ces attributions comprennent des options pour acheter 14 100 actions ordinaires à un prix d'exercice de 17,85 $ par action, correspondant au prix de clôture du 8 novembre 2024. De plus, les employés ont reçu des unités d'actions restreintes leur permettant d'acquérir 7 050 actions. Ces attributions d'actions ont été accordées dans le cadre du Plan d'Incitation 2020 de la Société, approuvé par le Conseil d'administration en janvier 2020 conformément à l'‘exception d'incitation’ de la règle 303A.08 du Manuel des Sociétés Côtées de la NYSE.

Arcus Biosciences (NYSE:RCUS) gab bekannt, dass sein Vergütungsausschuss an vier neue Mitarbeiter Aktienoptionen verliehen hat. Die Optionen umfassen die Möglichkeit, 14.100 Stammaktien zu einem Ausübungspreis von 17,85 $ pro Aktie zu erwerben, was dem Schlusskurs vom 8. November 2024 entspricht. Zusätzlich erhielten die Mitarbeiter beschränkte Aktienanteile zur Erwerbung von 7.050 Aktien. Diese Aktienoptionen wurden im Rahmen des Induktionsplans der Gesellschaft 2020 vergeben, der im Januar 2020 vom Vorstand gemäß der 'Induktionsausnahme' der Regel 303A.08 des NYSE-Listings genehmigt wurde.

Positive
  • None.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company’s common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual A2a/A2b receptor, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

Investor Inquiries:

Pia Eaves

VP of Investor Relations & Strategy

(617) 459-2006

peaves@arcusbio.com

Media Inquiries:

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Source: Arcus Biosciences

FAQ

How many shares were granted in Arcus Biosciences (RCUS) November 2024 inducement grants?

Arcus Biosciences granted options to purchase 14,100 shares and restricted stock units for 7,050 shares to four new employees.

What was the exercise price for RCUS stock options granted on November 8, 2024?

The exercise price for the stock options was $17.85 per share, which was the closing price on November 8, 2024.

Under which plan were the RCUS November 2024 equity awards granted?

The equity awards were granted under Arcus Biosciences' 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.

Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Stock Data

1.32B
54.37M
40.6%
60.05%
7.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD